Brought to you by 
Alnylam formalizes delivery deal with Inex
18 Mar 2011
Executive Summary
RNAi therapeutics developer Alnylam has expanded on an agreement signed last year with Inex (cancer treatments), this time licensing exclusive worldwide rights to Inex's liposomal delivery formulation technology that Alnylam was previously just evaluating. Alnylam intends to focus on a preclinical candidate targeting the PCSK9 gene for the treatment of hypercholesterolemia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Liposomes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam formalizes delivery deal with Inex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice